Competitive salary + benefits
Here's a great opportunity to develop your expertise within a
committed and recognised scientific team.
About the role
We are looking for a post-doctoral scientist to join our Safety
Pharmacology team for two years, to support a project addressing
translation from preclinical to clinical models. The project aims to
evaluate and improve the predictive value of preclinical cardiac
investigations, with a special focus on QRS prolongation as a marker
of pro- arrhythmic risk.
Your work will potentially influence the preclinical strategies that
are already in place within Global Safety Pharmacology, as well
as the risk assessment of candidate drugs before the first clinical
trials. For that reason, you can expect to be directly involved in
different preclinical models, from in-vitro screens up to in-vivo
telemetry studies. It is anticipated that the work will lead to scientific
publication, influencing both the drug selection process and the
PhD qualified, you will ideally hold a
animal experimentation. While a background in cardiovascular
pharmacology or toxicology would be ideal, we're equally interested
in any competence relating to the late phases of pre-clinical
development. You will also need technical and scientific skills in
both in-vitro and in-vivo electrophysiology, with broad knowledge of
preclinical risk assessment.
As one of the world's leading pharmaceutical companies,
AstraZeneca is focused on providing innovative, effective medicines
that make a real difference in key areas of healthcare. With 66,000
staff around the world, we invest $16 million every working day on
research and development.
For full details please click or visit:
quoting ref: SAUK113.
Read more about this position
and all other available jobs at